Deng Wen-Ying, Song Tao, Li Ning, Luo Su-Xia, Li Xiang
Department of Gastroenterology, Hennan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, Hennan, China E-mail :
Asian Pac J Cancer Prev. 2014;15(16):6565-70. doi: 10.7314/apjcp.2014.15.16.6565.
To observe the curative effects of rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer and analyze the correlation of CT perfusion (CTP) parameters and the expression of vascular endothelial growth factor (VEGF).
Twenty patients with esophageal cancer confirmed pathologically were randomly divided into combined treatment (rh-endostatin+DP regimen) group and single chemotherapy group, 10 patients in each group, respectively. All patients were given conventional CT examination and CTP imaging for primary tumor. The level of VEGF, the size of tumor and CTP parameters (BF, BV, PS and MTT) before treatment and after 2 cycles of treatment were determined for the comparison and the correlation between CTP parameters and VEGF expression was analyzed.
the therapeutic effect of rh-endostatin+DP regimen group was superior to single chemotherapy group. VEGF level after treatment in rh- endostatin +DP regimen group was obviously lower than single chemotherapy group (P<0.01). The expression of VEGF had positive correlation with BF and BV but negative correlation with MTT. Compared with treatment before for rh-endostatin +DP regimen group, BF, BV and PS decreased while MTT increased after treatment (P<0.05). However, there were no significant differences between treatment before and after treatment in single chemotherapy (P>0.05).
Rh-endostatin can down-regulate the expression of VEGF in esophageal cancer, change the state of hypertransfusion and high permeability of tumor vessels and had the better curative effect and slighter adverse reactions when combined with chemotherapy.
观察重组人血管内皮抑素联合DP方案治疗晚期食管癌患者的疗效，并分析CT灌注（CTP）参数与血管内皮生长因子（VEGF）表达的相关性。
将20例经病理确诊的食管癌患者随机分为联合治疗组（重组人血管内皮抑素+DP方案）和单纯化疗组，每组各10例。所有患者均接受常规CT检查及对原发肿瘤进行CTP成像。测定治疗前及2个周期治疗后VEGF水平、肿瘤大小及CTP参数（BF、BV、PS和MTT），进行比较并分析CTP参数与VEGF表达的相关性。
重组人血管内皮抑素+DP方案组的治疗效果优于单纯化疗组。重组人血管内皮抑素+DP方案组治疗后VEGF水平明显低于单纯化疗组（P<0.01）。VEGF表达与BF和BV呈正相关，与MTT呈负相关。重组人血管内皮抑素+DP方案组治疗后与治疗前比较，BF、BV和PS降低，MTT升高（P<0.05）。而单纯化疗组治疗前后差异无统计学意义（P>0.05）。
重组人血管内皮抑素可下调食管癌中VEGF的表达，改变肿瘤血管高灌注、高通透性状态，联合化疗时疗效更佳，不良反应更轻。
